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The biological effects of extremely low fre-
quency electromagnetic fields (ELF-EMF)
have been a concern since Wertheimer and
Leeper (1) reported that children living in
homes with an excess of electrical wiring
configurations suggestive of high current-
flow had a higher incidence of cancer.
However, subsequent in vivo, in vitro, and
epidemiological studies have produced vary-
ing results that often conﬂict with each other
(2–7). Whether ELF-EMF exposure is corre-
lated with human cancer is controversial and
therefore needs further research.
Carcinogenesis involves the irreversible
genetic alteration of a single cell (initiation),
followed by the clonal expansion of that initi-
ated cell (promotion), and the ultimate con-
version of these cells to invasive and metastatic
neoplastic cells (8). Mutation of DNA plays
an important role in carcinogenesis as evi-
denced by hereditary mutations predisposing
humans to cancer, known mutagens being
effective initiators of carcinogenesis, and
mutations found in the protooncogenes and
tumor-suppressor genes in cells of tumors (8).
If ELF-EMF contributes to cancer, then it is
important to determine the stage or stages of
carcinogenesis that it affects. Most studies
indicate that ELF-EMF is a nonionizing form
of radiation that is too weak to induce ther-
mal effects; therefore, it cannot damage or
mutate DNA and lead to mutagenesis (9,10).
A few studies have been interpreted as
indicating either mutagenic or comutagenic
activity (11,12). However, the weight of the
evidence indicates that ELF-EMF exposure
would be an extremely weak initiator, if not
a noninitiator, of carcinogenesis.
Assuming that ELF-EMF plays a role in
the carcinogenic process but that it is not a
carcinogenic initiator, it follows that ELF-
EMF is likely to be involved in the promo-
tional phase of cancer. The promotional
phase of carcinogenesis consists of nonmuta-
genic and epigenetic mechanisms (13). These
mechanisms entail the alteration of gene
expression at the transcriptional level (e.g.,
methylation of DNA or acetylation of DNA-
binding proteins), translational level (e.g.,
alternative splicing or stability of mRNA), 
or posttranslational level (e.g., protein modi-
fication such as phosphorylation). Most
tumor promoters are not mutagenic (e.g., phe-
nobarbital, phorbol esters, polybrominated
biphenyls, saccharin, peroxisome proliferators,
TCDD, DDT) (14), but can alter differentia-
tion (15), inhibit apoptosis (16,17), induce
various signal transduction pathways (e.g.,
protein kinase C, mitogen activated protein
kinases) (18), and activate gene expression
(19). Similar to tumor-promoting chemicals,
ELF-EMF can also alter the transcription and
translation of genes such as hsp70, myc, jun,
and fos (20–23).
To study the possibility that EMF con-
tributes to the promotional stage of cancer,
we chose a Friend erythroleukemia cell line to
determine the epigenetic effect of ELF-EMF,
in vitro, on cell proliferation and differentia-
tion. Friend erythroleukemia cells are primi-
tive erythroid cells that can be induced to 
differentiate after exposure to either DMSO
or hexamethylene bis-acetamide (HMBA). In
essence, this cell line mimics an initiated stem
cell. After exposure to these chemicals, these
cells differentiate as measured by their ability
to express globin mRNA and synthesize adult
hemoglobin, express a red cell membrane-
associated antigen, decrease in volume,
change morphologically, and exhibit limited
proliferative capacity (24,25). Tumor-pro-
moting effects should therefore inhibit differ-
entiation and stimulate proliferation of
DMSO-treated Friend erythroleukemia cells.
Such tumor-promoting effects have been
observed when Friend erythroleukemia cells
were treated with the known model tumor
promoter agent 12-O-tetradecanoylphorbol-
13-acetate (TPA) (26). Our results support
the hypothesis that ELF-EMF acts as a
tumor-promoting agent in mimicking the
tumor promoter TPA by inhibiting DMSO
and HMBA-induced Friend erythroleukemia
cell differentiation and by stimulating cell
proliferation.
Materials and Methods
Chemicals. DMSO was obtained from
Aldrich Chemical (Milwaukee, WI); acetic
acid from EM Science (Gibbstown, NJ);
formaldehyde (37%) from J.T. Baker
(Phillipsburg, NJ); ethanol from Millennium
Petrochemicals (Tuscola, IL); and HMBA
and benzidine from Sigma Chemical Co.
(St. Louis, MO).
Electromagnetic ﬁeld exposure system. We
used a Linear EMF Exposure System model
2 (LES-002-DC; Electric Research and
Management Inc., State College, PA). This
system consisted of one incubator (Steri-Cult
200; Forma Scientiﬁc, Marietta, OH), one
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Whether exposure of humans to extremely low frequency electromagnetic ﬁelds (ELF-EMF) can
cause cancer is controversial and therefore needs further research. We used a Friend ery-
throleukemia cell line that can be chemically induced to differentiate to determine whether ELF-
EMF could alter proliferation and differentiation in these cells in a manner similar to that of a
chemical tumor promoter. Exposure of this cell line to 60 Hz ELF-EMF resulted in a dose depen-
dent inhibition of differentiation, with maximal inhibition peaking at 40% and 40 mG (4 µT).
ELF-EMF at 10 mG (1.0 µT) and 25 mG (2.5 µT) inhibited differentiation at 0 and 20%,
respectively. ELF-EMF at 1.0 (100) and 10.0 G (1,000 µT) stimulated cell proliferation 50%
above the sham-treated cells. The activity of telomerase, a marker of undifferentiated cells,
decreased 100× when the cells were induced to differentiate under sham conditions, but when the
cells were exposed to 0.5 G (50 µT) there was only a 10× decrease. In summary, ELF-EMF can
partially block the differentiation of Friend erythroleukemia cells, and this results in a larger pop-
ulation of cells remaining in the undifferentiated, proliferative state, which is similar to the pub-
lished results of Friend erythroleukemia cells treated with chemical-tumor promoters. Key words:
cancer, cell differentiation, extremely low frequency electromagnetic ﬁelds, Friend leukemia cells,
telomerase activity. Environ Health Perspect 108:967–972 (2000). [Online 7 September 2000]
http://ehpnet1.niehs.nih.gov/docs/2000/108p967-972chen/abstract.htmlstock chamber, and two chambers that con-
tained the EMF-generating coils. Eight alter-
nating current magnetic coils per chamber
were arranged in groups of four with a
Merritt configuration, with the outer coils
bucking the inner coils to reduce the ﬁelds
outside the assembly. The coils were in biﬁlar
arrangement so that they could be energized
in parallel fields for sham conditions. The
incubator controlled the environment. Three
2.5-horsepower fans distributed air contain-
ing 5% CO2 at 98% relative humidity from
the incubator to the chambers through 6.4
cm polyvinyl chloride conduits. The cell cul-
ture chambers were at least 0.9 m from the
incubator to minimize the ELF-EMF expo-
sure from the incubator to less than the back-
ground levels. However, the chambers are
constructed from plastic and do not shield
from the earth’s magnetic field. The sham
ﬁelds were < 1 mG (0.1 µT). These chambers
were 85 × 85 × 90 cm (length × width ×
height) with the door positioned at the top,
the air intake 3 cm from the bottom, and the
outtake 25 cm from the top. Cell samples
were placed on a grid 10 cm from the bot-
tom and 7 cm above the intake port. ELF-
EMF exposure measurements of field
strengths using an EFA-1 Field Analyzer
probe (Wandel & Goltermann, Eningen,
Germany) indicated that the ELF-EMF ﬁelds
were homogeneous between 10 and 30 cm
above the grid; therefore, all samples were
placed in this homogeneous exposure zone
with the ﬂasks lying down in the horizontal
position. Thus, the EMF magnetic fields
were perpendicular to the plane of the ﬂask.
Also, the exposure system was characterized
through field measurements performed by
the National Institute of Standards and
Technology (NIST; Gaithersburg, MD).
Measurements of the magnetic field at the
sample plane showed a variation of 2–3%
from the speciﬁed ﬁeld, with a spatial unifor-
mity of > 99%. The measured electric ﬁeld
within the chambers at 10 G (1,000 µT)
magnetic ﬁeld strength was found to be < 0.2
V/m. There was no measurable distortion in
the 60 Hz magnetic field waveform. The
upper limits of ﬁeld strength and frequency
are 10 G (1,000 µT) and 3000 Hz, respec-
tively. Each chamber had a temperature
monitor and a three-axis magnetic sensor.
The incubator had outputs to allow the com-
puter to monitor temperatures, humidity,
and CO2 levels. The chambers also had ports
for monitoring CO2 levels, which was done
daily using a portable fyrite-based indicator
system. We also used the computer to set the
experiment in either a blind or known mode.
The absolute current induced within the
culture medium and within the cell is very
small. The maximum induced current in
the culture medium was calculated by using
either numerical simulation techniques or
the analytical expression for an insulated
rectangular box (27). The conductivity of
the medium was measured at 9.6 mS/m
using a Hanna Instrument conductivity
meter (Model HI 8733; Vila do Conde,
Portugal). Using ﬂask dimensions of 5.2 ×
4.8 cm, the maximum value of the current
density induced within the culture medium
was calculated to be 6.2 bo µÅ/m2, where bo
is the applied magnetic flux density in
Gauss. Thus, at 10 G the maximum induced
current density is 62 µÅ/m2. The maximum
induced current density occurs adjacent to
the walls of the ﬂask, while the current den-
sity at the center of the flask is zero. The
time-average power dissipated by the culture
medium is on the order of 2 × 10–12 W and
thus less than a 1 µJ of heat is generated
over a period of 3 days. Obviously, the ther-
mal effect from the small induced currents
is negligible.
Cell culture and induction of differentia-
tion. Friend erythroleukemia cell line 19-9
was maintained in Eagle’s basal medium (cat-
alog no. M-7278, lot 17H2380; Sigma
Chemical Co.) supplemented with 5% fetal
calf serum (catalog no. 16000-044, lot no.
1021367; Gibco BRL, Grand Island, NY),
and subcultured twice a week. We transferred
cells into fresh medium 1 day before the
induction of differentiation. For the induc-
tion of differentiation, we transferred the
cells to fresh medium containing 2% DMSO
or 4 mM HMBA at a cell density of 1 × 105
cells/mL, distributed to 25-cm2 cell-culture
ﬂasks with screw-on caps, and immediately
placed into the exposure and sham chambers.
The average time between the dilution of
cells in the DMSO or HMBA-containing
medium and placement of the ﬂasks into the
chambers was < 1 min. This was done to
minimize the time between the induction of
signal transduction pathways and the expo-
sure of these induced signaling pathways to
the ELF-EMF. We used flasks with screw-
top caps to minimize evaporation that could
induce osmotic stress, which is known to
induce cell-signaling pathways. We found
that the use of culture plates resulted in sig-
niﬁcant evaporation, which resulted in high
levels of differentiation in the absence of an
inducer. We did not see this effect when we
used the ﬂasks with screw-top caps that were
loosely screwed on.
Hemoglobin determination. Benzidine
staining technique. Benzidine was dissolved
in 12% acetic acid to a ﬁnal concentration of
0.4% (w/v). Just before the cells were stained
for hemoglobin, 40 µL of 30% H2O2 was
added to 1 mL 0.4% benzidine solution,
which was then added to a 5-mL cell suspen-
sion (25). The cells that stained dark blue-
green (Figure 1) were scored positive for
hemoglobin. We counted the stained versus
unstained cells using a hemocytometer, and
the results were expressed as a percentage of
cells that were stained. The undiluted cell
suspension was added to the hemocytome-
ter, and the cells were counted in ﬁve of the
nine grids (4 corners and the center grid),
with the total number of cells ranging
between 200 and 500 cells. The ﬁrst three
experiments at 1.0 G (100 µT) were counted
by two different individuals and the final
numbers agreed to within 1% of each other.
Immunostaining and flow cytometry.
Cells were collected and centrifuged at 200g
for 10 min and washed with phosphate-
buffered saline (PBS). This washing was
repeated 2 times, and then the cells were ﬁxed
in 4% formalin for 15 min. The membranes
of the ﬁxed cells were permeabilized for the
antibody step with 75% ethanol. Then the
cells were washed 1 time with 50% ethanol, 1
time with 25% ethanol, and 1 time with PBS.
These ﬁxed cells were resuspended for 1 hr in
a blocking agent containing 10% normal
goat serum that was dissolved in PBS. The
blocking step was continued for an additional
1 hr using a 1% solution of normal goat
serum and 0.1% bovine serum albumin in
PBS. A 1:200 dilution of the primary anti-
body was added to this cell suspension and
incubated overnight with constant shaking at
4°C. Then the cells were washed 3 times
with PBS, and the secondary antibody was
added at a 1:200 dilution in PBS containing
1% normal goat serum and 0.1% bovine
serum albumin for 1 hr at room temperature.
After incubation with the secondary anti-
body, the cells were washed 3 times with PBS
and resuspended in PBS at 1 × 105 cells/mL
and then analyzed using a Vantage ﬂuores-
cence activated cell sorter (FACS) (Becton;
Dickinson, San Jose, CA).
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Figure 1. A microscopic photograph at 200× illus-
trating benzidine-stained cells containing hemo-
globin versus unstained cells lacking hemoglobin.
The white and black arrows indicate benzidine-
positive and negative stained cells, respectively.Cell proliferation. Cells were seeded into
25-cm2 ﬂasks at 1 × 104 cells per ﬂask and
exposed to ELF-EMF or sham conditions.
The medium was changed every 2 days by
pelleting the cells at 200g and resuspending
in fresh medium. We determined cell densi-
ty by measuring DNA concentration. DNA
was quantiﬁed from cells that were collected
from ﬂasks and then centrifuged at 200g for
10 min, washed with PBS 2 times, and then
lysed in 3 mL 0.1 N NaOH. We determined
the DNA concentration (28) by measuring
the absorbance at 260 nm using a DU 7400
Beckman Diode Array Detector (Beckman
Coulter, Fullerton, CA).
Polymerase chain reaction-based telom-
erase assay. The cell suspension was cen-
trifuged and washed with PBS. This step was
repeated once and then cells were resuspend-
ed in PBS at a concentration of 1 × 106
cells/mL and aliquoted to three microcen-
trifuge tubes. After the cells were centrifuged
at 12,000g for 20 min and 4°C, the PBS was
carefully removed, and the cell pellets were
stored at –85°C. For the telomerase assay,
the cell pellet containing 1 × 106 cells was
thawed and diluted in 200 µL of 1× CHAPS
{3-[(3-cholamidopropyl) dimethyl-ammo-
nio]-1-propanesulfonate} buffer giving a
final cell concentration of 5,000 cells/µL
lysis buffer for 30 min at 4°C. Then the
samples were centrifuged at 12,000g for 20
min at 4°C. The cell lysate for each sample
was aliquoted to several new tubes and
stored at –85°C. We examined telomerase
activity by the telomeric repeat ampliﬁcation
protocol (TRAP) assay (29) using the
TRAPeze Telomerase Detection Kit (Oncor,
Gaithersburg, MD). This protocol includes
primers of a 36 base pairs (bp) internal
positive standard for ampliﬁcation, thus pro-
viding a positive control for accurate quanti-
tation of telomerase activity within a linear
range close to 2.5 logarithmic units. Each
analysis included a negative control
(CHAPS-lysis buffer instead of cell lysate), a
heat-inactivated control (sample incubated
at 85°C for 10 min before the assay), and a
positive control (breast carcinoma cell line
MCF-7). For RNase treatment, 10 µL of
extract was incubated with 1 µg of RNase
for 20 min at 37°C. The products of TRAP
assay were resolved by electrophoresis in a
non-denaturing 12% polyacrylamide gel
electrophoresis in a buffer containing 54
mM Tris-HCI (pH 8.0), 54 mM boric acid,
and 1.2 mM EDTA. The gel was stained
with Syber Green (Molecular Probes, Inc.,
Eugene, OR) and visualized at either 302
nm or 254 nm using an ultraviolet transillu-
minator. We captured and analyzed images
using a NucleoVision760 ccd cooled camera
image analyzer (NucleoTech Corporation,
San Mateo, CA). The products generated
from TRAP assay were quantiﬁed using the
following formula: 
TPG (total product generated units) = 
[(x – x0)/c]/]/[(r – r0)/cR] × 100, 
where x and x0 represent signals correspond-
ing to the TRAP product ladder bands of
non–heat-treated and heat-treated sample
lanes, respectively, and r and r0 represent sig-
nals from 1× CHAPS lysis buffer control (i.e.,
primer-dimer/polymerase chain reaction con-
tamination control) and TSR8 (DNA quanti-
tation control), respectively. The signal from
the internal standard (TSK1) in non–heat-
treated samples and TSR8 quantitative con-
trol are c and cR, respectively. 
Results
Both DMSO- and HMBA-induced Friend
erythroleukemia cells can be used to express
hemoglobin, a differentiation marker (Table
1). However, DMSO consistently caused a
higher percentage of cells to express hemo-
globin than HMBA-treated cells and was
chosen as the inducer of differentiation in
subsequent experiments. EMF-ELF at a ﬁeld-
strength of 1.0 G (100 mT) inhibited differ-
entiation 35% and 25% in DMSO and
HMBA-treated cells, respectively (Table 1).
A FACS technique was used as an alternative
method of quantifying the percentage of cells
containing hemoglobin. Figure 2 illustrates
how the data from the FACS analysis were
compiled. The channels were set according to
the results of several experiments that deter-
mined the ﬂuorescence proﬁles of Friend ery-
throleukemia cells ﬁxed without antibodies
and with secondary antibodies alone (data
not shown). Also, primary and secondary
antibodies were incubated with Friend ery-
throleukemia cells that were not treated with
a differentiating inducer. From these experi-
ments, the fluorescence intensity below b0
was attributed to the nonspeciﬁc binding of
secondary antibodies, and the fluorescence
intensities between a0 and b0 were from
background levels of ﬂuorescence in undiffer-
entiated cells (Figure 2). The number of
events in channel a0 and a1 was attributed to
the speciﬁc binding of the primary antibodies
to hemoglobin and the results were reported
as a ratio of ELF-EMF:sham (Figure 2).
Friend erythroleukemia cells treated with
DMSO and exposed to 1.0 G (100 µT) ELF-
EMF resulted in a shift of the peaks to lower
fluorescence intensities, thereby decreasing
the ELF-EMF:sham ratio to < 1.00 (Figure
2). An average ratio of 0.69 ± 0.22 was calcu-
lated from seven FACS experiments in which
the sham and ELF-EMF chamber each had
one ﬂask per experiment.
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Table 1. Inhibition of DMSO- or HMBA-induced differentiation of Friend erythroleukemia cells exposed to
1.00 G (100 µT), 60-Hz ELF-EMF.
Differentiation Percent differentiated cells Ratio of 
inducer Sham (+) EMF +EMF:sham
DMSO 28.9 ± 9.2 18.9 ± 8.1* 0.64 ± 0.14
HMBA 16.7 ± 4.7 12.2 ± 3.8* 0.74 ± 0.30
Hematocrit counting of benzidine-stained cells was used to determine the percentage of cells containing hemoglobin.
The data represent the percent average ± standard deviation at the 95% conﬁdence interval. There were three replicates
(ﬂasks) per experimental trial. There were 15 and 4 experimental trials for DMSO and HMBA treatments, respectively.
Ten of the 15 DMSO trials and none of the 4 HMBA trials were blind studies.
*Signiﬁcant at the p < 0.005 level as determined by a paired t-test.
Figure 2. An example of a FACS analysis showing the shift in ﬂuorescence intensity after exposure to 1.0
G (100 µT) ELF-EMF. The channels were set according to the results of previous experiments.
Fluorescence < b0 were seen in DMSO-treated cells incubated with only the secondary antibodies.
Fluorescence < a0 were seen in Friend cells incubated with primary and secondary antibodies but not
treated with DMSO. In channel a0 – a1, there were 3,152 events for sham and 1,832 events for EMF treat-
ment, with a ratio of EMF:Sham of 0.58. 
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on the differentiation of Friend ery-
throleukemia cells was dose dependent
(Table 2 and Figure 3). At 0.01 G (1 µT),
there was no signiﬁcant inhibition of differ-
entiation. Maximal inhibition occurred at
an approximate value of 0.05 G (5 µT).
Although the extent of differentiation varied
with each experiment at the various field
strengths, maximum inhibition was approx-
imately 40–50% (Table 2 and Figure 3).
The percentage of differentiating cells
appeared to be a function of passages. The
number of passages after the cells were
thawed from liquid nitrogen was < 5 for the
0–0.05 G (5 µT) experiments , 5–10 for the
experiments at 1.00 G (100 µT), and 10.0
G (1,000 µT), and 10–15 for the 0.10 and
0.50 G experiments. Apparently the cells
subjected to higher numbers of passages dif-
ferentiated less than cells that underwent
low numbers of passages. An ANOVA
showed no statistical differences among
0.05 G (5 µT), 0.1 G (10 µT), 0.5 G (50
µT), 1.0 G (100 µT), and 10 G (1,000 µT)
at the p = 0.001 level, indicating that the
level of inhibition by ELF-EMF was not a
function of differentiation levels. The varia-
tion between the different dose treatments
appeared to be a function of the number of
trials. The highest variance was observed at
1.00 G (100 µT), where there were 15 trial
experiments. The variation dropped almost
50% for the 0.05 G (5 µT) experiment that
had only two trials and dropped almost
75% for the remaining experiments that
only had one trial run.
Telomerase activity, a marker of undif-
ferentiated stemlike cells, was high in Friend
erythroleukemia cells grown in DMSO-free
media (Figure 4). Induction of differentia-
tion with DMSO caused a 100× decrease in
telomerase activity in the sham-treated cells
but only a 10× decrease in the ELF-EMF
(1.0 G, 100 µT) exposed cells. Cell prolifer-
ation was also affected by ELF-EMF (Figure
5). The DNA content, a marker of cell
number, increased 1.5 times compared to
the sham-treated cells after a 4-day exposure
to 1.0 G (100 µT) and 10.0 G (1,000 µT)
ELF-EMF.
Discussion
Driven by concerns raised by epidemiologic
studies suggesting a potential cancer risk after
exposures to ELF-EMF ﬁeld strengths above
the average exposure of 2 mG (0.2 µT)
(6,7,30), this study was designed to determine
whether there was a biological effect relevant
to the carcinogenic process. We used an in
vitro cell differentiation system to determine if
ELF-EMF could alter chemically induced dif-
ferentiation and proliferation of Friend ery-
throleukemia cells.
Our results, using two independent
assays to measure hemoglobin content,
demonstrated that inhibition of chemically
induced hemoglobin-containing cells by
ELF-EMF was dose dependent. In addition,
we showed that exposure to ELF-EMF after
chemical induction of differentiation in the
Friend cells blocked the reduction in telom-
erase activity. The reduction of telomerase
activity is a normal consequence of cells ter-
minally differentiating or senescing (31). The
corollary experiment to the induction of dif-
ferentiation is a measurement of the exposed
population of the Friend cells to proliferate as
measured by DNA synthesis. The result was
an increase in cell proliferation, which was
probably the consequence of a larger subpop-
ulation of undifferentiated cells that did not
lose their capacity to proliferate.
Our results contrast to those reported by
Revoltella et al. (32). They saw no effect of
ELF-EMF on the proliferation and differen-
tiation of a Friend erythroleukemia cell line.
We can only speculate on an explanation of
the differences between their system and
ours. One could be differences in the strain
of Friend cells used. After induction of cell
differentiation by DMSO, Revoltella et al.’s
cell line continued to proliferate to the same
level as the cells not treated with DMSO.
Our cell line had decreased proliferation
when treated with either DMSO or HMBA.
Also, we minimized the time between the
exposure to DMSO and ELF-EMF so that
the inhibitory effect of ELF-EMF on the cell
signaling pathways induced by DMSO was
almost immediate. The difference of time
between DMSO and ELF-EMF exposure in
Revoltella et al.’s experiments were not
reported (32), so we are unable to make the
comparisons. This may be important because
the DMSO-induced differentiation process
has two distinct phases (i.e., pre- and post-
commitment), and TPA is known to inhibit
the precommitment stage (33). Also, their
ELF-EMF coils were placed at the top and
bottom, whereas ours were placed on each
side of the growth chambers. This could also
be a potential explanation of the differences
because Blackman et al. (34–36) demonstrat-
ed that ELF-EMF perpendicular to the static
ﬁelds of the earth had the greatest effect on
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Table 2. Dose response of various field strengths at 60-Hz ELF-EMF on the differentiation of Friend 
erythroleukemia cells.
Field strength,  Percent differentiated cells
G (µT) Sham  (+) EMF EMF:sham
0.00 (0) 40.5 ± 0.9 41.5 ± 2.1 1.02
0.01 (1) 32.8 ± 2.7 34.1 ± 4.1 1.04
0.025 (2.5) 52.6 ± 2.7 46.4 ± 2.0 0.88
0.05 (5) 40.0 ± 5.2 26.4 ± 2.7* 0.66
0.10 (10) 15.2 ± 1.4 10.7 ± 1.7* 0.70
0.50 (50) 16.1 ± 0.4 9.8 ± 1.1* 0.61
1.00 (100) 28.9 ± 9.2 18.9 ± 8.1* 0.65
10.0 (1,000) 24.8 ± 2.0 12.7 ± 3.5* 0.51
Hematocrit counting of benzidine-stained cells was used to determine the percentage of cells containing hemoglobin.
Each experiment had three to four replicates (ﬂasks). There was one experiment trial per EMF dose, except for at 0.05
and 1.00 G (100 µT), where there were 2 and 15 experiments done, respectively.
*The averages between the sham and ELF-EMF-exposed cells were signiﬁcant at the p < 0.001 level as determined by a
paired t-test for DMSO-induced differentiated cells. 
Figure 3. Dose response of DMSO-induced differ-
entiation of Friend erythroleukemia cells exposed
to various field strengths. The data are ELF-
EMF:sham ratios calculated from the data pre-
sented in Table 2. NEL, no effect level.
1.25
1.00
0.75
0.50
0.25
0.00
0.0 0.1 5.0 10.0
Field strength (G)
%
 
D
i
f
f
e
r
e
n
t
i
a
t
e
d
 
c
e
l
l
s
NEL
Telomerase
activity
DMSO:
EMF (0.5 G):
– ++
–– +
Densiometric values:
Relative ratios:
4,258 46  442
100 1 10
Internal
control
Figure 4. The effect of 1.0 G (100 µT) ELF-EMF on
telomerase activity. Telomerase activity was mea-
sured using the TRAP assay. The internal control
was used to quantify the signal ampliﬁcation efﬁ-
ciency among the samples. The densiometric val-
ues were measured using our Nucleotech gel doc
scanning system.neurite outgrowth of PC-12 cells, whereas
fields applied parallel to the earth’s static
ﬁelds resulted in no difference.
Because the potential risk of cancer has
been a primary concern of ELF-EMF expo-
sures, understanding both the mechanisms
of carcinogenesis and the potential relevance
of our in vitro system must be delineated.
Carcinogenesis is a multistage, multimecha-
nism process (37,38), consisting of initia-
tion, promotion, and progression phases.
The weight of the evidence appears to have
negated the possibility of a mutagenic or ini-
tiating potential of ELF-EMF fields (39).
Consequently, if ELF-EMF exposure con-
tributes to the carcinogenic process, it must
act as a tumor promoter. Therefore, by iden-
tifying characteristics of tumor promoters,
and assuming ELF-EMF as a physical agent
has properties identical to chemical promot-
ers, such as phorbol esters, phenobarbital,
and dioxin, it should have the ability to alter
differentiation (40), to stimulate the clonal
expansion of initiated cells by either or both
stimulation of proliferation (13), and to
block apoptosis (41). In addition, many
tumor promoters seem to have threshold lev-
els of no effect (42,43).
It might seem that the use of an estab-
lished erythroleukemia cell line and the
results obtained from these cells would have
no relevance to the potential mechanistic
role that ELF-EMF might have in carcino-
genesis. The carcinogenic initiation process
is one that blocks the ability of a clonally
expandable cell (possibly a stemlike cell) to
terminally differentiate and become immor-
talized (13). In the promotion phase this
initiated cell clonally expands so that addi-
tional genotypic and phenotypic changes
occur to bring about an invasive, metastatic
neoplastic cell (13). Therefore, our results
indicate that the process of inducing a kind of
terminal differentiation, as measured by the
expression of the globin gene and the produc-
tion of hemoglobin in an erythroleukemia
line, can be inhibited by ELF-EMF. In other
words, these ELF-EMF ﬁelds mimic some of
the properties of known chemical tumor
promoters such as TPA.
In the absence of precise knowledge of
the mechanisms by which DMSO induces
Friend erythroleukemia cell differentiation, it
is difﬁcult to discuss the mechanisms of its
inhibition by ELF-EMF. However, the most
obvious physical mechanism produced by
exposing cell cultures to a 60-Hz magnetic
field is the creation of an induced electric
current both within the electrically conduct-
ing culture medium and within the cells
themselves. Because the size of the sample is
small compared to the wavelength of the ﬁeld,
the induced current may be estimated using
Faraday’s law. Modeling of the container,
medium, and free-ﬂoating cells reveals that a
circulating current is produced within the cul-
ture medium roughly proportional to the
distance from the center of the flask. This
current passes tangentially around the insulat-
ing cell membrane. A much smaller circulat-
ing current is induced within the cell itself,
proportional to the distance from the center
of the cell. Thus, a signiﬁcant tangential shear
current exists at the cell membrane. The ratio
of the external to internal current at the mem-
brane is roughly proportional to the ratio of
the product of the medium conductivity and
distance of the cell from the center of the ﬂask
to the product of the conductivity of the cell
and the cell radius. Assuming that the con-
ductivities of the medium and the cell are
roughly the same, the ratio of external to
internal shear current for a 5-µm diameter cell
located near the edge of the 5.2 × 4.8 cm ﬂask
is on the order of 5 cm/0.00025 cm =
20,000. This result has been veriﬁed through
simulations using the finite element tech-
nique. We therefore speculate that the EMFs
probably interfere with the DMSO or
HMBA membrane-trigger signal transduction
system needed to alter, epigenetically, the
gene expression found in the hemoglobin-
containing cells. This may be due to the cur-
rents induced within individual cell’s plasma
membranes or the external to internal shear
current difference of 20,000 as calculated
above. However, the EMF effect on a plasma
membrane signaling protein is probably not
from the external current alone. At 0.05 G (5
µT) and 10 G (1,000 µT), we calculated an
induced current density of 62 µÅ/m2 and
0.31 µÅ/m2 at the walls of the ﬂask, respec-
tively. Although this was a 200× difference
between 0.05 G (5 µT) and 10 G (1,000 µT),
the final result of EMF-induced inhibition
was similar between these ﬁeld strengths, indi-
cating that external currents alone may not be
the critical factors in controlling the differen-
tiation potential of these cells.
Finally, we can ask the question, what
might be the relevance of these data on
mouse erythroleukemia cells to the potential
induction of human cancers by ELF-EMF?
Any biological effect of one in vitro experi-
ment cannot be automatically equated to the
entire and complex carcinogenic process in
human beings. However, if the biological
effect is real and relevant to one of the mech-
anisms of human carcinogenesis (in this case,
the blocked differentiation in the tumor pro-
motion phase), ELF-EMF exposure must be
further examined in more direct and relevant
experimental systems. In a human popula-
tion, if ELF-EMF ﬁelds can act as a potential
human tumor promoter, then the individual
being exposed needs to have initiated cells
on which ELF-EMF can act (to stimulate
the clonal expansion), and be at a field
strength above a threshold level, and the
individual must also be exposed regularly for
a chronic length of time. Consequently, any
epidemiological study must be designed to
test ELF-EMF as a tumor promoter, not
simply as a potential carcinogen. The design
must be a mechanistically based, biologically
relevant model of carcinogenesis. 
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